Journal: American Journal of Physiology - Renal Physiology

Article Title: Loss of circadian gene Bmal1 in the collecting duct lowers blood pressure in male, but not female, mice

doi: 10.1152/ajprenal.00364.2019

Figure Lengend Snippet: Urinary endothelin (ET)-1 excretion during the active phase of the last day of normal-salt diet (A and D), high-salt diet (B and E), or high-salt diet + the ET type B (ETB) receptor antagonist A-192621 (C and F) treatment. Data are presented for the active phase. Student’s t test was used to compare CDBmal1KO vs. flox mice: *P < 0.05.

Article Snippet: Urinary ET-1 concentrations were determined by ELISA (QuantiGlo ET-1 Kit, R&D Systems, Minneapolis, MN).

Techniques:

Journal: American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

Article Title: Renal denervation attenuates hypertension but not salt sensitivity in ET B receptor-deficient rats

doi: 10.1152/ajpregu.00174.2017

Figure Lengend Snippet: ET-1 levels during normal salt and high-salt diets. A: plasma endothelin-1 (ET-1) content. B: renal inner medullary ET-1 content. C: renal production of ET-1 measured by 24-h urinary excretion of ET-1. DNx, denervated; TG, transgenic; ETB, endothelin B. aP < 0.05 vs. TG sham; bP < 0.05 vs. TG DNx; cP < 0.05 vs. ETB-def sham; one-way ANOVA with Tukey’s post hoc test for multiple comparisons (A–C). *P < 0.05 active vs. inactive period by two-way ANOVA; two-way ANOVA with Sidak’s post hoc test for multiple comparisons (C). TG sham, n = 6; TG DNx, n = 5; ETB-def sham, n = 7; ETB-def DNx, n = 6.

Article Snippet: Urine and plasma ET-1 concentrations were measured via ELISA (QET00B; R&D Systems).

Techniques: Transgenic Assay

Journal: Life sciences

Article Title: Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes

doi: 10.1016/j.lfs.2016.02.067

Figure Lengend Snippet: 24 week old non-diabetic Wistar (Nondiabetic) and diabetic GK (diabetic) rats were treated for 4 weeks with 166 mg/kg-chow linagliptin (Nondiabetic+Linagliptin, Diabetic+Linagliptin). (A). Blood glucose levels were assessed via tail vein puncture before and after treatment. While the diabetic rats had significantly elevated blood glucose levels compared to the nondiabetic rats, no significant changes were observed in either group following treatment. (B). Linagliptin treatment reduced plasma ET-1 levels significantly in the diabetic rats, however they were not returned to the plasma levels observed in the nondiabetic rats. Results are expressed as mean ± SEM, n=3–5, ***p<0.001 vs Nondiabetic, ###p<0.001 vs Diabetic.

Article Snippet: ET-1 levels in the plasma of both linagliptin treated and untreated Wistar and GK rats were assessed using the QuantiGlo Endothelin-1 ELISA kit (Bioteck, R&D, USA) according manufacturer’s protocol and reported as total ET-1 levels.

Techniques:

Journal: Life sciences

Article Title: Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes

doi: 10.1016/j.lfs.2016.02.067

Figure Lengend Snippet: Basilar arteries harvested from rats from each group were mounted on a DMT wire myograph for assessment of vascular function. (A). Dose response curves to ET-1 in Nondiabetic, Nondiabetic+Linagliptin, Diabetic, and Diabetic+Linagliptin were performed. (B). Diabetic arteries exhibited an increase in maximum contractile response compared to Nondiabetic arteries, and linagliptin treatment reduced this response in each group. (C). Total contraction response was improved in the diabetic group following treatment with linagliptin. (D) There was no statistically significant difference in sensitivity to ET-1 among the groups. Contractile response expressed as % increase from baseline and the results are given as mean ± SEM, n=3–5, *=p<0.05 vs. Nondiabetic, #=p<0.05 vs. Diabetic)

Article Snippet: ET-1 levels in the plasma of both linagliptin treated and untreated Wistar and GK rats were assessed using the QuantiGlo Endothelin-1 ELISA kit (Bioteck, R&D, USA) according manufacturer’s protocol and reported as total ET-1 levels.

Techniques:

Journal: Life sciences

Article Title: Linagliptin reduces effects of ET-1 and TLR2-mediated cerebrovascular hyperreactivity in diabetes

doi: 10.1016/j.lfs.2016.02.067

Figure Lengend Snippet: (A). Dose response curve to ET-1 shows that antagonism of TLR2 reduces the contractile response in diabetic GK arteries (Diabetic+antiTLR2). (B). Maximum contractile response to ET-1 was decreased following TLR2 antagonism with no effect on (C) sensitivity to ET-1. (D) Dose response curve to ACh shows that antagonism of TLR2 increases endothelium dependent vasorelaxation. (E). Total relaxation response to ACh was increased following TLR2 antagonism with no effect on (F) sensitivity to ACh. Results are given as mean ± SEM, n=6/group, *=p<0.05 vs. Diabetic.

Article Snippet: ET-1 levels in the plasma of both linagliptin treated and untreated Wistar and GK rats were assessed using the QuantiGlo Endothelin-1 ELISA kit (Bioteck, R&D, USA) according manufacturer’s protocol and reported as total ET-1 levels.

Techniques: